Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Details : huMNC2-CAR22 bears the “1XX” mutations in the T cell’s CD3-z signaling domain, targeting MUC1*, the growth factor receptor that drives the growth and metastasis of most solid tumor cancers.
Product Name : huMNC2-CAR22
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
September 01, 2023
Reset All
